US 11,905,327 B2
Single-domain antibodies and variants thereof against TIGIT
Wang Zhang, Jiangsu (CN); Shu Wu, Jiangsu (CN); Shuai Yang, Jiangsu (CN); Qi Pan, New York, NY (US); and Chuan-Chu Chou, Westfield, NJ (US)
Assigned to Nanjing Legend Biotech Co., Ltd., Nanjing (CN)
Appl. No. 16/958,397
Filed by Nanjing Legend Biotech Co., Ltd., Jiangsu (CN)
PCT Filed Dec. 28, 2018, PCT No. PCT/CN2018/124979
§ 371(c)(1), (2) Date Jun. 26, 2020,
PCT Pub. No. WO2019/129221, PCT Pub. Date Jul. 4, 2019.
Claims priority of application No. PCT/CN2017/119506 (WO), filed on Dec. 28, 2017; and application No. PCT/CN2018/097159 (WO), filed on Jul. 26, 2018.
Prior Publication US 2021/0054071 A1, Feb. 25, 2021
Int. Cl. C07K 16/02 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2803 (2013.01) [A61P 35/00 (2018.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); A61K 2039/505 (2013.01); C07K 2317/22 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/569 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)] 18 Claims
 
1. An anti-TIGIT construct comprising a single-domain antibody (sdAb) moiety specifically recognizing TIGIT, wherein the sdAb moiety comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 36; a CDR2 comprising the amino acid sequence of SEQ ID NO: 106; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 176.